Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response
Clinical Genitourinary Cancer
· Elsevier
The publisher did not provide an abstract — full text is available via the link below.
Read at publisher →
Cite
Get new articles on “Urology”
Subscriptions, keyword tracking and favourites — in the Articlium Telegram bot.
Open in Telegram
Citation
✕
ГОСТ
APA
MLA
BibTeX
Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response. // Clinical Genitourinary Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S155876732600131X?dgcid=rss_sd_all
Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response. Clinical Genitourinary Cancer. https://www.sciencedirect.com/science/article/pii/S155876732600131X?dgcid=rss_sd_all
“Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response.” Clinical Genitourinary Cancer.
@article{article88810,
title = {Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response},
journal = {Clinical Genitourinary Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S155876732600131X?dgcid=rss_sd_all}
}